GlassScriptPhysician profile
Huyi Jin Kim
NPI 1669678231
$1,637.30
in general payments reported to CMS, 2019-2025
25 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $93.50 · 2021: $730 · 2022: $139 · 2024: $13.24 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $189.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.36 | 2019-2022 | |
| Amgen INC. | $190.33 | 2019-2022 | |
| Inari Medical, INC. | $176.00 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $142.32 | 2019-2021 | |
| Glaxosmithkline, LLC. | $126.95 | 2019-2021 | |
| Abbvie INC. | $69.75 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $56.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $56.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.12 | 2019 | |
| Pfizer INC. | $53.58 | 2019-2021 | |
| Amarin Pharma, INC. | $50.74 | 2021 | |
| Abbott Laboratories | $45.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.81 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $39.40 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.70 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2022 | |
| Mylan Specialty L.P. | $29.89 | 2021 | |
| Lilly USA, LLC | $25.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.24 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.19 | 2022 | |
| Eisai INC. | $15.91 | 2021 | |
| Melinta Therapeutics, LLC | $14.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2021 | |
| Shire North American Group INC | $13.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huyi Jin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.